MUC16 and neoplasm: Tumor markers determined from blood samples, such as the prostate-specific antigen (PSA), alpha-fetoprotein and cancer antigen 125 (CA-125), have already been introduced into clinical practice to support the diagnosis and/or monitoring of prostate, liver and ovarian cancers.